Metagenomi Therapeutics, Inc.(MGX)Stock Analysis

MGX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Metagenomi Therapeutics, Inc. (MGX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MGX at 6.4/100 on a 32-signal composite quality model, placing it at rank #2,842 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.1) and free cash flow (3.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Metagenomi Therapeutics, Inc. reports quarterly revenue of $1.2M, net income of $-23.1M, free cash flow of $-21.2M. Top institutional holders of MGX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, Catalio Capital Management,, based on the most recent SEC filings. MGX trades on the Nasdaq exchange and files with the SEC under CIK 1785279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Metagenomi Therapeutics, Inc. directly from SEC EDGAR. Metagenomi Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 29 since 2025, currently 6.4 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.